Helius Medical Technologies Receives First Of Two Human Performance Patents

NEWTOWN, Pa.--(BUSINESS WIRE)--Helius Medical Technologies, Inc. (TSX:HSM, and HSM.W and OTCQB:HSDT) (“Helius” or the “Company”) announced today that it has been issued its first method patent (U.S. Patent No. 9,656,069) that features claims directed to the use of the PoNS™ device for human performance improvement rather than rehabilitation therapy. The ‘069 patent is the first member of the existing family of patents the company has received for its core asset, the PoNS device, in the field of human performance improvement. Potential uses could include supporting physical and cognitive improvements in healthy adults, or more leisurely pursuits such as improving a golf-swing. This recent patent further reinforces the current family of PoNS patents protecting various forms of physical and cognitive therapy in combination with both skin and oral cavity stimulation using the PoNS device or any equivalent neurostimulation device that the company may develop.

The Company has now been issued or has allowed 53 US and international patents covering medical device features, physical and cognitive therapies, human performance methods, and design features associated with the PoNS device.

“This patent significantly expands our potential addressable market and helps Helius continue to build its intellectual property estate for our PoNS therapy,” said CEO Philippe Deschamps.

About PoNS™ Therapy

The Portable Neuromodulation Stimulator (PoNS) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS Therapy combines the use of the device with physical or cognitive therapy and is currently being evaluated in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to moderate Traumatic Brain Injury.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. For more information, please visit www.heliusmedical.com.

The Toronto Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Cautionary Disclaimer Statement:

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws (“forward-looking statements”).

All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding the potential uses of the PoNS™ Therapy in human performance improvement, and the related potential expansion of the Company’s market opportunity.

Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the necessity of conducting successful clinical testing to establish safety and effectiveness of the PoNS Therapy for human performance improvement, the requirement for regulatory approval for marketing for human performance improvement prior to the Company’s ability to commercialize the PoNS Therapy for such indications, and other risks detailed from time to time in the filings made by the Company with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking statement. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Risks and uncertainties about the Company’s business are more fully discussed in the Company’s Transition Report on Form 10-K for the period ended December 31, 2016 and the Company’s, which has been filed with the United States Securities and Exchange Commission and the Canadian securities regulators and which can be obtained from either at www.sec.gov or www.sedar.com, and the Company’s other filings with the SEC and Canadian securities regulators from time to time.